CompletedNot Applicable

Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma

Taiwan70 participantsStarted 1996-06

Plain-language summary

To evaluate the therapeutic effectiveness of H. pylori eradication in stage IE \& IIE-1 primary low-grade B cell lymphoma of MALT of the stomach

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. No enlargement of peripheral or mediastinal lymph node;
✓. Peripheral blood smear revealing no leukemic or lymphomatous abnormalities;
✓. Predominant of alimentary tract lesions with any adenopathy corresponding to accepted lymphatic drainage route; and
✓. No involvement of liver or spleen except by extension of contiguous disease .

What they're measuring

evaluate the efficacy of Helicobacter pylori eradication therapy with respect to objective regression rate and time to disease progression of primary low-grade gastric MALToma.

Timeframe: Four weeks after the completion of anti-H. pylori therapy by CT scan

Trial details

NCT IDNCT00201422

SponsorNational Health Research Institutes, Taiwan

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2004-01

View on ClinicalTrials.gov More MALT Lymphoma trials